NVO
Novo Nordisk A/S
NVO offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
STX
Seagate Technology Holdings plc
STX has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
STX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
STX's revenue, profitability, cash flow and balance sheet are all currently strong.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over STX in the historical PE scenario, which offers more potential upside but is not a forecast.
STX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.9x | $188 | -65% |
| Forward | 12x | $545 | — |
| Fair | 17x | $318 | -42% |
| Current | 29x | $545 | — |
| Expensive | 43x | $823 | +51% |
Historical ranges are pointers, not guarantees.
STX's PE is in its expensive range at 29x. If earnings grow as analysts expect, today's price would be 12x next year's earnings, in its cheap range.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
STX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
STX has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
STX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.99 | +147% |
| Q3 2026 | $19.06 | +145% |
| Q2 2026 | $13.90 | +105% |
| Q1 2026 | $10.54 | +51% |
| Q4 2025 | $8.84 | +60% |
| Q3 2025 | $7.79 | +101% |
| Q2 2025 | $6.77 | +328% |
| Q1 2025 | $6.96 | +$8.26 |
| Q4 2024 | $5.51 | +$9.02 |
STX's earnings per share have climbed steadily: $19.06 over the past year, up 145% from the year before, and higher year over year for 10 quarters in a row.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
STX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.2B | +61% |
| Q2 2026 | $3.6B | +48% |
| Q1 2026 | $3.1B | +44% |
| Q4 2025 | $2.8B | +22% |
| Q3 2025 | $2.6B | +21% |
| Q2 2025 | $2.4B | +30% |
| Q1 2025 | $2.2B | +31% |
| Q4 2024 | $2.3B | +50% |
STX has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 49% | +22 points |
| Q2 2026 | 43% | +20 points |
| Q1 2026 | 32% | +12 points |
| Q4 2025 | 30% | +8.9 points |
| Q3 2025 | 26% | +7.8 points |
| Q2 2025 | 23% | +6.6 points |
| Q1 2025 | 20% | +11 points |
| Q4 2024 | 21% | +13 points |
STX has the edge over NVO on profitability, with a higher operating margin.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
STX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +246% |
| Q2 2026 | $1.1B | +163% |
| Q1 2026 | $953M | +341% |
| Q4 2025 | $607M | +305% |
| Q3 2025 | $427M | +1481% |
| Q2 2025 | $425M | +12% |
| Q1 2025 | $216M | +69% |
| Q4 2024 | $150M | +52% |
STX has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over STX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
STX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +3M shares |
| 1 year | +2.7% | +6M shares |
| 3 years | +12% | +24M shares |
| 5 years | +0.4% | +1M shares |
| Available history | -12% | -33M shares |
STX has 232M diluted shares, up 2.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $400M |
| Q2 2026 | $117M |
| Q1 2026 | $30M |
| Q4 2025 | — |
| Q3 2025 | $29M |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
STX spent $547M buying back its own shares over the past year.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
STX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.2x | Very low |
| Q2 2026 | 0.4x | Very low |
| Q1 2026 | 0.8x | Very low |
| Q4 2025 | 1.2x | Healthy |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 1.9x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.8x | Moderate |
STX has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
STX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.5 | Neutral |
| Stochastic | 8.3 | Oversold |
STX's weekly RSI is 40 (neutral) and its Stochastic is 8 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over STX on valuation relative to its sector.
STX PE vs Technology Sector
| Metric | STX | Sector median | Relative |
|---|---|---|---|
| PE | 29x | 28x | 2.7% above |
| PE % | 75 | 35 | 40 pts above |
STX is trading at 29x earnings, in line with the Technology sector's median of 28x.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
STX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $683.6 | 20% below |
| 20 week MA | $785.0 | 31% below |
| 50 week MA | $630.7 | 14% below |
| 100 week MA | $387.3 | 41% above |
| 200 week MA | $234.4 | 133% above |
STX has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
STX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $59.6 | $63.0 | +5.7% |
| 2021 | $63.0 | $111.4 | +77% |
| 2022 | $111.4 | $50.5 | -55% |
| 2023 | $50.5 | $85.4 | +69% |
| 2024 | $85.4 | $87.4 | +2.4% |
| 2025 | $87.4 | $286.2 | +228% |
| 2026 YTD | $286.2 | $545.1 | +90% |
STX has the edge over NVO on returns for 2026, with the stronger performance.